Summary

Eligibility
for people ages 18 years and up (full criteria)
Healthy Volunteers
healthy people welcome
Location
at San Francisco, California
Dates
study started
estimated completion
Principal Investigator
by Raymond Cho, MD, PhD
Headshot of Raymond Cho
Raymond Cho

Description

Summary

This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

Details

This is a one-arm, open-label study to examine the effect of Guselkumab . Guselkumab is a FDA-approved medication for the treatment of psoriasis. This study will examine how Guselkumab affects immune cells within scalp psoriasis lesions. Ten subjects with moderate to severe scalp psoriasis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with Guselkumab treatment response.

Keywords

Psoriasis of Scalp, Psoriasis, Guselkumab

Eligibility

You can join if…

Open to people ages 18 years and up

possess a PSSI (psoriasis scalp severity index) of ≥12

You CAN'T join if...

  1. taking systemic immunosuppressives in the last 4 weeks
  2. pregnancy
  3. severe immunodeficiency (either from genetic or infectious causes).
  4. tuberculosis or other active serious infection
  5. active systemic malignancy.
  6. breast-feeding
  7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  8. Males who are trying to conceive

    -

Location

  • UCSF accepting new patients
    San Francisco California 94115 United States

Lead Scientist at UCSF

  • Raymond Cho, MD, PhD
    Dr. Cho is a physician and geneticist who investigates the molecular basis of skin disease. With colleague Dr. Jeffrey Cheng, he co-leads the RashX initiative at UCSF, which develops high resolution molecular fingerprints to understand and treat unusual skin diseases.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT05858632
Phase
Phase 4 Psoriasis Research Study
Study Type
Interventional
Participants
Expecting 10 study participants
Last Updated